Scientists in the department of Advanced Organ Bioengineering and Therapeutics (Faculty of S&T, TechMed Centre) recently published a novel cancer immune therapy in the scientific journal Nature Communications. In their research, Prof Dr. Jai Prakash and his team developed newly designed nanoparticles which can target the body's immune cells to turn them against cancer.
Characterization and uptake of M2-targeted nanoliposomes. a Representative illustration of nanoliposomes showing incorporation of HSPC, PAPC and PGPC phospholipid. b Typical histogram showing the size distribution of HSPC nanoliposomes (HSPC-L, HSPC:Cholesterol = 8:2), PAPC-L (PAPC:HSPC:Cholesterol = 3:5:2) and PGPC-L (PGPC:HSPC:Cholesterol = 3:5:2) obtained from dynamic light scattering method. c Typical chromatogram of lipid mixtures isolated from PAPC-L and PGPC-L, analyzed using ultra-high performance liquid chromatography (uHPLC) with corona charged aerosol detector (CAD). d Stability analysis of nanoliposomes using size measurement in culture media at 37 °C during 24 h. e–g Representative fluorescent images of cellular uptake of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine (DiI)-containing HSPC-L, PAPC-L and PGPC-L by M1 and M2 differentiated macrophages from THP-1 monocytes at t = 2 h. Blue: DAPI, Red: nanoliposomes labeled with DiI, scale bar = 50 µm. f Representative flow cytometry histograms and liposomal uptake (mean fluorescent intensity (MFI)) of HSPC-L, PAPC-L (3:5:2) or PGPC-L (3:5:2) by M1 and M2 macrophages after incubation for 2 h (left to right: ***p = 0.000037, *p = 0.012). g Liposomal uptake (MFI) of PAPC-L (2:6:2, 1:7:2) or PGPC-L (2:6:2) by M1 and M2 macrophages after incubation for 2 h (left to right: **p = 0.0013, *p = 0.031). Data represent the mean + standard error of the mean (SEM) from three independent experiments. Statistical analysis was performed with Multiple…